Literature DB >> 24155048

Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population.

Kai-Feng Pan1, Luca Formichella, Lian Zhang, Yang Zhang, Jun-Ling Ma, Zhe-Xuan Li, Cong Liu, Yu-Mei Wang, Gereon Goettner, Kurt Ulm, Meinhard Classen, Wei-Cheng You, Markus Gerhard.   

Abstract

Helicobacter pylori-specific proteins are involved in gastric carcinogenesis. To investigate the seroprevalence of six H. pylori-specific antibodies in patients with different gastric histology, and the impact of seropositivities on the evolution of precancerous gastric lesions, a follow-up study was conducted in Linqu County, China. The seropositivities for CagA, VacA, GroEL, UreA, HcpC and gGT were assessed by recomLine analysis in 573 H. pylori-positive subjects and correlated with evolution of precancerous gastric lesions. We found that the score of H. pylori recomLine test was significantly increased in subjects with chronic atrophic gastritis (CAG, p < 0.0001) or intestinal metaplasia (IM, p = 0.0125), and CagA was an independent predictor of advanced gastric lesions, adjusted odds ratios (ORs) were 2.54 (95% CI = 1.42-4.55) for IM and 2.38 (95% CI = 1.05-5.37) for dysplasia (DYS). Moreover, seropositivities for CagA and GroEL were identified as independent predictors for progression of gastric lesions in a longitudinal study, and ORs were 2.89 (95% CI = 1.27-6.59) and 2.20 (95% CI = 1.33-3.64), respectively. Furthermore, the risk of progression was more pronounced in subjects with more than three positive antigens (p(for) trend = 0.0003). This population-based study revealed that seropositivities for CagA and GroEL might be potential markers to identify patients infected with high-risk H. pylori strains, which are related to the development of GC in a Chinese high-risk population, and recomLine test might serve as a tool for risk stratification.
© 2013 UICC.

Entities:  

Keywords:  Helicobacter pylori; gastric cancer; precancerous gastric lesions; protein; serology

Mesh:

Substances:

Year:  2013        PMID: 24155048     DOI: 10.1002/ijc.28560

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Biomarkers for Helicobacter pylori infection and gastroduodenal diseases.

Authors:  Seiji Shiota; Yoshio Yamaoka
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

2.  Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population.

Authors:  Yu-Mei Wang; Zhe-Xuan Li; Fu-Bing Tang; Yang Zhang; Tong Zhou; Lian Zhang; Jun-Ling Ma; Wei-Cheng You; Kai-Feng Pan
Journal:  Tumour Biol       Date:  2015-09-10

Review 3.  Implementation of gastric cancer screening - the global experience.

Authors:  Mārcis Leja; Weicheng You; M Constanza Camargo; Hiroshi Saito
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-09-28       Impact factor: 3.043

4.  Validation of a Blood Biomarker for Identification of Individuals at High Risk for Gastric Cancer.

Authors:  Meira Epplein; Wei-Cheng You; Julia Butt; Yang Zhang; Laura H Hendrix; Christian C Abnet; Gwen Murphy; Wei Zheng; Xiao-Ou Shu; Shoichiro Tsugane; You-Lin Qiao; Philip R Taylor; Taichi Shimazu; Keun-Young Yoo; Sue K Park; Jeongseon Kim; Sun Ha Jee; Tim Waterboer; Michael Pawlita; Kai-Feng Pan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-29       Impact factor: 4.254

Review 5.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

6.  Anti-Helicobacter pylori Antibody Profiles in Epstein-Barr virus (EBV)-Positive and EBV-Negative Gastric Cancer.

Authors:  M Constanza Camargo; Kyoung-Mee Kim; Keitaro Matsuo; Javier Torres; Linda M Liao; Douglas R Morgan; Angelika Michel; Tim Waterboer; Jovanny Zabaleta; Ricardo L Dominguez; Yasushi Yatabe; Sung Kim; Erick R Rocha-Guevara; Jolanta Lissowska; Michael Pawlita; Charles S Rabkin
Journal:  Helicobacter       Date:  2015-08-07       Impact factor: 5.753

7.  Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.

Authors:  Huakang Tu; Liping Sun; Xiao Dong; Yuehua Gong; Qian Xu; Jingjing Jing; Qi Long; W Dana Flanders; Roberd M Bostick; Yuan Yuan
Journal:  Int J Cancer       Date:  2014-06-19       Impact factor: 7.396

Review 8.  Diagnosis of Helicobacter pylori infection: Current options and developments.

Authors:  Yao-Kuang Wang; Fu-Chen Kuo; Chung-Jung Liu; Meng-Chieh Wu; Hsiang-Yao Shih; Sophie S W Wang; Jeng-Yih Wu; Chao-Hung Kuo; Yao-Kang Huang; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

9.  A possible role of GDDR in the development of Helicobacter pylori-associated gastric cancer.

Authors:  Zhanwei Zhao; Fei Wang; Cheng Fang; Gang Wang; Jianbo Shuang; Guanghui Chu; Sijun Hu; Lin Chen; Jianjun Du
Journal:  Tumour Biol       Date:  2016-02-03

10.  Impact of Coinfection with Schistosoma mansoni on the Antibody Response to Helicobacter pylori.

Authors:  Ashraf Fawzy Mosa Ahmed; Mona Hassan El-Sayad; Hala Shehata Ali; Hend Aly El-Taweel
Journal:  Acta Parasitol       Date:  2021-02-17       Impact factor: 1.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.